TABLE 1

Pulmonary inflammation in a murine asthma model: eosinophil and IL-13 accumulation in BALF

Mice sensitized to OVA by systemic exposure (days 1 and 6) were challenged with either aerosolized saline or OVA (days 13 and 14), the latter inducing an asthmatic response. TG100-115 was administered as an aerosolized 0.4% formulation (days 12-14) and dexamethasone as a systemic treatment (days 8-14). BALF collected on day 16 was analyzed to determine eosinophil counts (represented as percentage of total cells) and IL-13 levels. Data shown as means ± S.E.M. (n = 8-9). For both endpoints, the vehicle treatment/OVA challenge group differed from all others by P < 0.001. For the IL-13 measure only, TG100-115 and dexamethasone groups differ by P < 0.01.